drugset / Trial / NCT05583266

Efficacy of Pentoxifylline on Cerebrovascular Function in Patients With Cerebral Small Vessel Disease(PERFORM)

NCT05583266

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blinded, placebo-controlled, multi-center trial. Cerebral small vessel disease (CSVD) patients will be diagnosed according to STRIVE standards and randomized into the Pentoxifylline sustained-release tablet group and placebo group. The purpose of this trial is to assess the efficacy of Pentoxifylline sustained- release tablets on CSVD.

Timeline

Start
2022-11-01
Primary completion
2023-03-03
Completion
2024-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Pentoxifylline Small molecule